Influenza is a common respiratory infectious disease that spreads rapidly and is prone to mutation. According to statistics from the World Health Organization (WHO), there are approximately 1 billion cases of seasonal influenza worldwide each year. Vaccination is one of the most economical and effective means of preventing and controlling influenza. On January 15, 2025, Si Longlong’s team from the Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, published two important research results in the two top international journals Nature Microbiology and Nature Chemical Biology at the same time, providing a new idea for the development of influenza vaccines. Breakthrough 1: Constructing a PROTAR influenza vaccine library to expand vaccine diversity Traditional vaccines have poor immune effects and safety risks when facing frequent virus mutations, and the development cycle is long and complicated. In 2022, Si Longlong’s team pioneered the PROTAR attenuated live vaccine technology, ...
On January 21, Baili Tianheng released its 2024 performance forecast, expecting to achieve annual operating income of approximately 5.8 billion yuan, a year-on-year increase of 932.27%; the net profit attributable to the parent company’s owners is expected to be 3.6 billion yuan, an increase of 4.38 billion yuan from the same period last year, and will turn losses into profits. The notice disclosed that this significant performance growth was mainly due to the irrevocable, non-deductible down payment of US$800 million paid by the company’s overseas partner Bristol-Myers Squibb (BMS) for its core product BL-B01D1 during the reporting period, which led to a significant increase in the company’s operating income. BL-B01D1 is a dual-antibody ADC targeting EGFR×HER3. It is the world’s first and only drug of its kind to enter the clinical stage. At the end of 2023, SystImmune, a wholly-owned subsidiary of Baili Tianheng, reached an exclusive licensing and cooperation ...
At present, my country’s medical security has entered a new stage of high-quality development with rapid expansion, deepening reform and continuous innovation. It has carried out 10 batches of national organized drug centralized procurement and 5 batches of national organized high-value medical consumables centralized procurement, including a total of 435 kinds of drugs, and commonly used high-value medical consumables cover cardiology, orthopedics, etc. At the beginning of 2025, my country’s medicine centralized procurement ushered in a new opportunity to “go out”. Recently, the China-ASEAN Regional Medicine Centralized Procurement Platform was officially launched in Fangchenggang City, Guangxi. It is the first cross-border medicine regional centralized procurement platform guided by the National Medical Security Administration. Build an open pharmaceutical procurement cooperation platform According to reports, the China-ASEAN Regional Pharmaceutical Procurement Platform is responsible for carrying out joint procurement in some regions of China and ASEAN countries. It will explore innovative regional medical, ...
Chengda Bio announced in the evening that the application for registration and marketing authorization of the quadrivalent influenza virus split vaccine (referred to as “quadrivalent influenza vaccine”) developed by its wholly-owned subsidiary Chengda Bio (Benxi) Co., Ltd. in China has recently received the “Acceptance Notice” from the State Food and Drug Administration. https://finance.eastmoney.com/
On January 24, Fosun Pharma (600196/02196) issued an announcement that the drug registration application for salbutamol hydrochloride nebulized inhalation solution of its holding subsidiary Fosun Pharma (Xuzhou) Co., Ltd. was recently accepted by the State Drug Administration. The drug is a chemical drug independently developed by the company, mainly used to treat or prevent bronchospasm caused by reversible airway obstructive diseases in adults and children over 6 years old. As of December 2024, the group’s cumulative R&D investment in the drug is approximately 4.54 million yuan. According to data provided by IQVIA, the sales of salbutamol hydrochloride nebulized inhalation solution in China in 2023 will be approximately 1.009 billion yuan. The announcement pointed out that the drug still needs to pass GMP compliance inspection and obtain drug registration approval before commercial production, so the acceptance of the drug registration application will not have a significant impact on the group’s current ...
On January 24, in order to effectively prevent and stop monopoly behavior in the pharmaceutical sector and safeguard consumer interests and social public interests, the State Council Anti-monopoly and Anti-unfair Competition Committee formulated and issued the “Anti-monopoly Guidelines for the Pharmaceutical Sector” (hereinafter referred to as the “Guidelines”). The “Guidelines” have 7 chapters and 55 articles. Aiming at the prominent monopoly problems in the pharmaceutical sector, they further refine the behavior, law enforcement principles and identification standards of monopoly behavior in the pharmaceutical sector. The “Guidelines” refine the behavior of monopoly agreements in the pharmaceutical sector. First, they list typical horizontal and vertical monopoly agreements in the pharmaceutical sector, and clarify the identification principles and ideas of anti-monopoly law enforcement agencies; Second, they summarize the behavior of new monopoly agreements in the pharmaceutical sector, and summarize the considerations for the application of the “Anti-monopoly Law” to reverse payment agreements; Third, ...
Recently, Johnson & Johnson released its 2024 Q4 and full-year annual results. It was disclosed that the revenue in Q4 last year was US$22.52 billion, a year-on-year increase of 5.26%. Net profit was US$3.431 billion, a year-on-year decrease of 15.26%. In 2024, the company achieved revenue of US$88.821 billion, a year-on-year increase of 4.3%, and a year-on-year increase of 7% excluding the impact of exchange rates. The full-year net profit attributable to ordinary shareholders was US$14.066 billion, a year-on-year decrease of 59.99% compared with US$35.153 billion in the same period last year. Among them, global Johnson & Johnson’s innovative pharmaceutical sales were US$57 billion, a year-on-year increase of 5.8%. Global Johnson & Johnson Medical Technology sales were US$31.9 billion, a year-on-year increase of 4.8%. https://finance.sina.com.cn/
On January 22, Fosun Pharma issued an evening announcement stating that the special resolution on the privatization of Henlius by its holding subsidiary Fosun New Drug through absorption merger was not approved at the H-share class shareholders’ meeting. Therefore, the absorption merger will not be implemented and Henlius will retain its H-share listing status. The announcement showed that the proposal was mainly opposed by small and medium-sized shareholders. At the interim shareholders’ meeting of Henlius, it was approved by more than two-thirds (including the number) of shareholders with voting rights who attended the meeting, but at the class shareholders’ meeting where only H-share shareholders had voting rights, the proportion of dissenting votes reached 19.25%, exceeding the 10% upper limit stipulated in the acquisition regulations. Fosun Pharma said that it regretted the failure of the Henlius privatization proposal and fully respected the decision of all shareholders. Fosun Pharma will continue to ...
Recently, the FDA officially approved Datroway (datopotamab deruxtecan, Dato-DXd), an innovative antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo, for the treatment of unresectable or metastatic hormone receptor (HR)-positive, HER2-negative adult breast cancer patients who have received endocrine therapy and chemotherapy. The key basis for the approval of Dato-DXd for breast cancer indications was the positive results of its Phase III clinical study TROPION-Breast01. In the TROPION-Breast01 study, Dato-DXd showed efficacy advantages. Compared with the standard therapy selected by the researchers, the drug successfully reduced the risk of disease progression or death in patients by 37%. This data means that in patients treated with Dato-DXd, the rate of disease deterioration has slowed significantly, giving patients more survival time and treatment opportunities. Specifically, progression-free survival (mPFS) was significantly extended from 4.9 months in the control group to 6.9 months in the trial group. In terms of safety assessment, a key concern ...
Recently, the 2024 DR equipment public bidding and procurement list was released, and domestic medical equipment won 10 of the 12 lists, marking the transformation of domestic substitution towards innovative applications. Wandong Medical has the highest market share and has dominated the list for more than ten consecutive years, deserving the title of DR King. In fact, the overall situation of DR equipment in 2024 is not optimistic. According to statistics from Zhongcheng Data Science, the overall market size of medical device bidding in China decreased by 21.1% year-on-year in 2024, with the DR equipment market also decreasing by 21.5%. The reasons for the decline are the multiple impacts of medical policies, technological innovations, and competitive trends. From the perspective of procurement trends, the market is divided into two levels: centralized procurement and high-level hospitals, which means higher requirements are placed on domestic medical equipment. It is worth mentioning that ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.